Suppr超能文献

核受体超家族的结构概述:对生理学和治疗学的深入了解。

Structural overview of the nuclear receptor superfamily: insights into physiology and therapeutics.

机构信息

Department of Pharmacology, and Center for Molecular Design, University of Virginia Health System, Charlottesville, VA 22908, USA.

出版信息

Annu Rev Physiol. 2010;72:247-72. doi: 10.1146/annurev-physiol-021909-135917.

Abstract

As ligand-regulated transcription factors, the nuclear hormone receptors are nearly ideal drug targets, with internal pockets that bind to hydrophobic, drug-like molecules and well-characterized ligand-induced conformational changes that recruit transcriptional coregulators to promoter elements. Yet, due to the multitude of genes under the control of a single receptor, the major challenge has been the identification of ligands with gene-selective actions, impacting disease outcomes through a narrow subset of target genes and not across their entire gene-regulatory repertoire. Here, we summarize the concepts and work to date underlying the development of steroidal and nonsteroidal receptor ligands, including the use of crystal structures, high-throughput screens, and rational design approaches for finding useful therapeutic molecules. Difficulties in finding selective receptor modulators require a more complete understanding of receptor interdomain communications, posttranslational modifications, and receptor-protein interactions that could be exploited for target gene selectivity.

摘要

作为配体调控的转录因子,核激素受体是近乎理想的药物靶点,其内部口袋可与疏水性、类似药物的分子结合,并具有特征明确的配体诱导构象变化,从而募集转录共激活因子到启动子元件。然而,由于单个受体控制的基因数量众多,主要的挑战一直是鉴定具有基因选择性作用的配体,通过少数目标基因而不是整个基因调控谱来影响疾病结果。在这里,我们总结了甾体和非甾体受体配体开发的概念和迄今为止的工作,包括晶体结构、高通量筛选和合理设计方法的使用,以寻找有用的治疗分子。发现选择性受体调节剂的困难需要更全面地了解受体的域间通讯、翻译后修饰和受体-蛋白相互作用,这些可以被利用来实现靶基因的选择性。

相似文献

1
Structural overview of the nuclear receptor superfamily: insights into physiology and therapeutics.
Annu Rev Physiol. 2010;72:247-72. doi: 10.1146/annurev-physiol-021909-135917.
2
Structure and function of the human nuclear xenobiotic receptor PXR.
Curr Drug Metab. 2005 Aug;6(4):357-67. doi: 10.2174/1389200054633844.
6
Role of orphan nuclear receptors in the regulation of drug-metabolising enzymes.
Clin Pharmacokinet. 2003;42(15):1331-57. doi: 10.2165/00003088-200342150-00003.
7
The ROR nuclear orphan receptor subfamily: critical regulators of multiple biological processes.
Prog Nucleic Acid Res Mol Biol. 2001;69:205-47. doi: 10.1016/s0079-6603(01)69048-2.
8
CIA, a novel estrogen receptor coactivator with a bifunctional nuclear receptor interacting determinant.
Mol Cell Biol. 2001 Jan;21(1):343-53. doi: 10.1128/MCB.21.1.343-353.2001.
9
Coregulators of estrogen receptor action.
Crit Rev Eukaryot Gene Expr. 2002;12(1):1-22. doi: 10.1615/critreveukaryotgeneexpr.v12.i1.10.

引用本文的文献

1
Targeting pregnane X receptor with a potent agonist-based PROTAC to delay colon cancer relapse.
Oncogenesis. 2025 Aug 30;14(1):34. doi: 10.1038/s41389-025-00573-2.
2
Small Molecules Targeting the Structural Dynamics of AR-V7 Partially Disordered Proteins Using Deep Ensemble Docking.
J Chem Theory Comput. 2025 May 13;21(9):4898-4909. doi: 10.1021/acs.jctc.5c00171. Epub 2025 Apr 15.
4
Structural basis for the ligand-dependent activation of heterodimeric AHR-ARNT complex.
Nat Commun. 2025 Feb 3;16(1):1282. doi: 10.1038/s41467-025-56574-7.
6
Transcriptional Cofactors for Thyroid Hormone Receptors.
Endocrinology. 2025 Jan 6;166(2). doi: 10.1210/endocr/bqae164.
9
Nuclear Receptors and the Hidden Language of the Metabolome.
Cells. 2024 Jul 31;13(15):1284. doi: 10.3390/cells13151284.
10
Mechanism of antagonist ligand binding to REV-ERBα.
Sci Rep. 2024 Apr 10;14(1):8401. doi: 10.1038/s41598-024-58945-4.

本文引用的文献

1
Allosteric effects govern nuclear receptor action: DNA appears as a player.
Sci Signal. 2009 Jun 2;2(73):pe34. doi: 10.1126/scisignal.273pe34.
5
DNA binding site sequence directs glucocorticoid receptor structure and activity.
Science. 2009 Apr 17;324(5925):407-10. doi: 10.1126/science.1164265.
6
7
Significance of peroxisome proliferator-activated receptors in the cardiovascular system in health and disease.
Pharmacol Ther. 2009 Jun;122(3):246-63. doi: 10.1016/j.pharmthera.2009.03.003. Epub 2009 Mar 24.
9
Structural basis for the activation of PPARgamma by oxidized fatty acids.
Nat Struct Mol Biol. 2008 Sep;15(9):924-31. doi: 10.1038/nsmb.1474.
10
Deconstructing estradiol: removal of B-ring generates compounds which are potent and subtype-selective estrogen receptor agonists.
Bioorg Med Chem Lett. 2009 Feb 15;19(4):1250-3. doi: 10.1016/j.bmcl.2008.12.080. Epub 2008 Dec 24.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验